Hagop Kantarjian Selected Research

Residual Neoplasm

1/2021	Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia.
1/2021	Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
1/2021	Immunotherapy in Acute Myeloid Leukemia: Where We Stand.
1/2020	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
1/2019	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.
2/2018	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
1/2018	The emerging role of immune checkpoint based approaches in AML and MDS.
1/2018	Molecular remission as a therapeutic objective in acute promyelocytic leukemia.
1/2018	SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
12/2017	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hagop Kantarjian Research Topics

Disease

211	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/2022 - 01/2000
186	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 01/2002
125	Neoplasms (Cancer) 10/2022 - 01/2002
120	Leukemia 09/2022 - 03/2002
113	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 01/2002
112	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 03/2002
72	Philadelphia Chromosome 01/2022 - 02/2002
40	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 03/2002
37	Primary Myelofibrosis (Myelosclerosis) 12/2021 - 09/2002
34	Hematologic Neoplasms (Hematological Malignancy) 01/2022 - 01/2002
27	Acute Promyelocytic Leukemia 01/2020 - 05/2003
24	Thrombocytopenia (Thrombopenia) 01/2022 - 04/2004
23	Blast Crisis (Blast Phase) 01/2021 - 10/2002
23	Residual Neoplasm 01/2021 - 11/2006
20	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2021 - 06/2002
18	Anemia 01/2022 - 03/2002
18	Myeloid Leukemia (Leukemia, Myelocytic) 01/2021 - 04/2006
17	Disease Progression 12/2021 - 05/2002
15	Infections 01/2022 - 03/2003
15	Lymphoma (Lymphomas) 01/2022 - 06/2005
14	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 05/2002
11	Splenomegaly 01/2018 - 03/2002
11	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2008 - 09/2002
10	Pneumonia (Pneumonitis) 01/2022 - 01/2003
10	Multiple Myeloma 10/2017 - 03/2003
10	Polycythemia Vera 04/2017 - 06/2003
9	Exanthema (Rash) 01/2021 - 06/2009
9	Pathologic Complete Response 07/2020 - 01/2003
9	Neutropenia 02/2019 - 09/2003
9	Nausea 09/2018 - 10/2002
9	Hypereosinophilic Syndrome (Loeffler Endocarditis) 06/2013 - 09/2002
8	Hemorrhage 11/2019 - 06/2009
8	Fever (Fevers) 10/2018 - 01/2003
7	Diarrhea 01/2017 - 12/2003
7	Systemic Mastocytosis 09/2013 - 05/2004
7	Essential Thrombocythemia 08/2013 - 01/2003
6	Hypertension (High Blood Pressure) 12/2020 - 01/2011
6	Burkitt Lymphoma (Burkitt's Lymphoma) 12/2020 - 03/2002
6	Sepsis (Septicemia) 07/2020 - 08/2004
6	Cytopenia 01/2020 - 06/2007

Drug/Important Bio-Agent (IBA)

148	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 01/2000
85	Tyrosine Kinase InhibitorsIBA 01/2022 - 11/2006
56	Cytarabine (Cytosar-U)FDA LinkGeneric 05/2022 - 03/2002
37	Dasatinib (BMS 354825)FDA Link 11/2020 - 06/2006
36	Decitabine FDA Link 12/2021 - 03/2003
32	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2002
30	Pharmaceutical PreparationsIBA 10/2021 - 04/2004
28	Phosphotransferases (Kinase)IBA 06/2018 - 12/2003
23	Rituximab (Mabthera)FDA Link 12/2021 - 11/2003
23	fludarabineIBA 12/2021 - 03/2003
23	nilotinib FDA Link 03/2016 - 07/2005
22	bcr-abl Fusion ProteinsIBA 01/2022 - 01/2000
21	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 03/2002
21	Monoclonal AntibodiesIBA 01/2021 - 09/2004
20	Azacitidine (5 Azacytidine)FDA Link 01/2019 - 01/2005
19	Arsenic Trioxide (Trisenox)FDA Link 01/2021 - 05/2003
19	Clofarabine (Clolar)FDA Link 01/2021 - 10/2003
18	ponatinibIBA 09/2022 - 11/2012
18	Inotuzumab OzogamicinIBA 01/2022 - 06/2013
18	Vincristine (Oncovin)FDA LinkGeneric 10/2021 - 03/2002
16	Tretinoin (Retinoic Acid)FDA LinkGeneric 11/2019 - 05/2003
15	InterferonsIBA 01/2021 - 03/2003
15	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018 - 01/2003
14	Gemtuzumab (Mylotarg)FDA Link 01/2020 - 01/2002
13	ruxolitinibIBA 01/2021 - 04/2010
13	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 01/2000
12	venetoclaxIBA 05/2022 - 03/2014
12	blinatumomabIBA 01/2022 - 01/2017
12	ibrutinibIBA 12/2021 - 06/2014
12	Dexamethasone (Maxidex)FDA LinkGeneric 10/2021 - 03/2002
12	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 03/2002
11	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2002
11	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 12/2008
11	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 12/2003
11	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 05/2015 - 03/2003
10	Lenalidomide (CC 5013)FDA Link 10/2022 - 05/2007
10	Hemoglobins (Hemoglobin)IBA 07/2018 - 06/2004
9	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 06/2014
9	CytokinesIBA 12/2021 - 09/2002
9	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 12/2008
9	fms-Like Tyrosine Kinase 3IBA 01/2020 - 05/2004
8	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 03/2002
8	Alemtuzumab (Campath)FDA Link 06/2013 - 11/2005
7	Biological ProductsIBA 01/2021 - 05/2004
7	HomoharringtonineIBA 01/2019 - 01/2007
7	Prednisone (Sone)FDA LinkGeneric 12/2018 - 09/2010
7	Methotrexate (Mexate)FDA LinkGeneric 01/2016 - 03/2002
7	Alkylating AgentsIBA 06/2012 - 05/2004
7	tipifarnib (R115777)IBA 03/2011 - 10/2002
6	CreatinineIBA 01/2022 - 10/2008

Therapy/Procedure

287	Therapeutics 10/2022 - 03/2002
98	Drug Therapy (Chemotherapy) 07/2022 - 03/2002
23	Stem Cell Transplantation 01/2022 - 07/2003
20	Salvage Therapy 01/2022 - 04/2003
14	Hematopoietic Stem Cell Transplantation 01/2020 - 02/2007
14	Induction Chemotherapy 01/2017 - 01/2003
8	Transplantation 01/2022 - 09/2003
7	Drug Tapering 11/2020 - 12/2003
6	Radiotherapy 10/2022 - 09/2004
6	Cell Transplantation 01/2022 - 01/2007